Radioactive therapy takes aim at resistant childhood cancer

NCT ID NCT00107289

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a radioactive drug called I-MIBG in people with resistant neuroblastoma or related tumors (pheochromocytoma and paraganglioma). The drug is designed to deliver radiation directly to cancer cells. Researchers want to see if it can shrink tumors and how safe it is. The trial is open to patients whose cancer has not responded to standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radioactive iodine (I-131 MIBG)
What this could lead to: If it works, this could offer a treatment option for patients with resistant neuroblastoma or related tumors that have not responded to standard therapy.
What could go wrong: This is a phase 2 trial, so it is still early. The treatment may not shrink tumors in all patients, and there are risks from radiation exposure, including potential damage to healthy tissues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT PARAGANGLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant adrenal gland pheochromocytoma neuroblastoma paraganglioma pheochromocytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA PHEOCHROMOCYTOMA

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.